Filella X, Molina R, Jo J, Umbert B, Bedini J L, Ballesta A M
Department of Clinical Biochemistry, Hospital Clínic i Provincial, Barcelona, Spain.
Tumour Biol. 1990;11(6):289-94. doi: 10.1159/000217664.
Serum prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) levels were measured in 70 patients with benign prostatic hypertrophy (BPH) and in 70 patients with prostatic cancer. PSA was increased above the cutoff level of 10 ng/ml in 13% of patients with BPH and in 87% of patients with prostatic cancer. In contrast, abnormal PAP levels were found in 14 and 76% of patients, respectively. We concluded that, due to its high specificity, PSA is a useful marker in the management of patients with prostatic carcinoma and that it surpasses PAP in this regard.
对70例良性前列腺增生（BPH）患者和70例前列腺癌患者测定了血清前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）水平。在BPH患者中，13%的患者PSA升高超过10 ng/ml的临界值，而在前列腺癌患者中这一比例为87%。相比之下，PAP水平异常的患者分别为14%和76%。我们得出结论，由于其高特异性，PSA是前列腺癌患者管理中的一种有用标志物，在这方面它优于PAP。
